fluoxetine has been researched along with cholecalciferol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Marchi, I; Rudaz, S; Selman, M; Veuthey, JL | 1 |
| Djazayery, A; Hosseini, A; Jazayeri, S; Khoraminya, N; Tehrani-Doost, M | 1 |
| Camargo, A; da Silva, EB; Dalmagro, AP; Rikel, L; Simão da Silva, KAB; Zeni, ALB | 1 |
| B Neis, V; B Zeni, AL; Camargo, A; Dalmagro, AP; F Rosado, A; P Kaster, M; Platt, N; S Rodrigues, AL | 1 |
| Camargo, A; Dafre, AL; de Almeida, GRL; de O Dalsenter, Y; Engel, WD; Moretti, M; Neis, VB; Platt, N; Rodrigues, ALS; Rosa, PB; Rosado, AF; Selhorst, I; Werle, I | 1 |
| He, T; Liu, B; Wen, C | 1 |
1 trial(s) available for fluoxetine and cholecalciferol
| Article | Year |
|---|---|
Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Calcifediol; Cholecalciferol; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales | 2013 |
6 other study(ies) available for fluoxetine and cholecalciferol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Evaluation of the influence of protein precipitation prior to on-line SPE-LC-API/MS procedures using multivariate data analysis.
Topics: Alanine; Blood Proteins; Chemical Precipitation; Cholecalciferol; Chromatography, Liquid; Flunitrazepam; Fluoxetine; Mass Spectrometry; Methadone; Multivariate Analysis; Online Systems; Pyrrolidines; Solid Phase Extraction | 2007 |
Cholecalciferol counteracts depressive-like behavior and oxidative stress induced by repeated corticosterone treatment in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cholecalciferol; Corticosterone; Depression; Disease Models, Animal; Fluoxetine; Humans; Lipid Peroxidation; Male; Mice; Motor Activity; Oxidative Stress; Toxicity Tests, Acute; Toxicity Tests, Subchronic; Treatment Outcome; Vitamins | 2018 |
Cholecalciferol abolishes depressive-like behavior and hippocampal glucocorticoid receptor impairment induced by chronic corticosterone administration in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Beclin-1; Behavior, Animal; Cholecalciferol; Corticosterone; Depression; Fluoxetine; Hippocampus; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Microtubule-Associated Proteins; Receptors, Glucocorticoid | 2020 |
Involvement of serotonergic neurotransmission in the antidepressant-like effect elicited by cholecalciferol in the chronic unpredictable stress model in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cholecalciferol; Depression; Female; Fluoxetine; Hindlimb Suspension; Humans; Mice; Serotonin; Synaptic Transmission | 2022 |
Identifying interstitial lung disease associated chemicals by integrating transcriptome-wide association study and chemical-gene interaction networks.
Topics: Cholecalciferol; Fluoxetine; Humans; Lung Diseases, Interstitial; Quality of Life; Transcriptome | 2023 |